In addition to neutralizing antibodies, strategies aimed to alleviate tumor angiogenesis also include antisense oligonucleotides that target VEGF [16], soluble decoy VEGF receptors [17], and small molecule inhibitors that target VEGF-A–VEGFR-2 signaling [18]. The gene discussed is KDR; the disease is neoplasm.